SRC and neoplasm: The GPR35–Na/K-ATPase–Src pathway is precisely targetable with GPR35-selective pepducins.10 Its upstream role in tumour tissue remodelling renders GPR35 an attractive target, even in cases where tumour cells themselves do not express the receptor.